{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:44:10Z","timestamp":1791081850616,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":4573,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1111\/j.1538-7836.2010.03791.x","type":"journal-article","created":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T11:12:52Z","timestamp":1265022772000},"page":"1147-1158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Platelet pharmacogenomics"],"prefix":"10.1016","volume":"8","author":[{"given":"C.S.","family":"ZUERN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"SCHWAB","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"GAWAZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"GEISLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrg1428","article-title":"Pharmacogenetics \u2013 five decades of therapeutic lessons from genetic diversity","volume":"5","author":"Meyer","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics \u2013 drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0020","series-title":"Pharmacology and Therapeutics. Principles to Practice","first-page":"225","article-title":"Heterogeneity of drug responses and individualization of therapy","author":"Kirchheiner","year":"2008"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.tig.2009.07.007","article-title":"Understanding cardiovascular disease through the lens of genome\u2010wide association studies","volume":"25","author":"Arking","year":"2009","journal-title":"Trends Genet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2009.39","article-title":"Clinically available pharmacogenomics tests","volume":"86","author":"Flockhart","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/01.ATV.0000043664.48689.7F","article-title":"PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extracellular matrix proteins","volume":"22","author":"Sajid","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0045","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","article-title":"Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa","volume":"110","author":"Szczeklik","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1345\/aph.1E227","article-title":"Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?","volume":"39","author":"Papp","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2000.02300.x","article-title":"Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa)","volume":"110","author":"Andrioli","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0060","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.CIR.101.9.1013","article-title":"Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists","volume":"101","author":"Michelson","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0065","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM199604253341703","article-title":"A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis","volume":"334","author":"Weiss","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(97)80010-4","article-title":"PIA1\/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis","volume":"349","author":"Ridker","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0075","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/01.CIR.99.8.1005","article-title":"PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement","volume":"99","author":"Kastrati","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0080","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-0037-1615644","article-title":"Platelet glycoprotein receptor IIIa polymorphism PLA1\/PLA2 and coronary risk: a meta\u2010analysis","volume":"85","author":"Di Castelnuovo","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1160\/TH03-06-0341","article-title":"PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction","volume":"91","author":"Gorchakova","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0735-1097(00)00709-9","article-title":"PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement","volume":"36","author":"Kastrati","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0049-3848(02)00356-0","article-title":"PLA1\/A2 polymorphism of the platelet glycoprotein receptor IIb\/IIIa in young patients with cryptogenic TIA or ischemic stroke","volume":"108","author":"Van Goor","year":"2002","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1055\/s-0037-1615054","article-title":"Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA\u20101b\/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease","volume":"79","author":"Zotz","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0105","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/blood.V89.6.1939","article-title":"Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence","volume":"89","author":"Kunicki","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0110","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood.V93.8.2449","article-title":"Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients","volume":"93","author":"Santoso","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(98)06448-4","article-title":"Association of two silent polymorphisms of platelet glycoprotein Ia\/IIa receptor with risk of myocardial infarction: a case\u2013control study","volume":"353","author":"Moshfegh","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0120","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V95.5.1560.005k43_1560_1564","article-title":"Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen","volume":"95","author":"Matsubara","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0125","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1161\/hc3801.096397","article-title":"Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction","volume":"104","author":"Croft","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2004.03.021","article-title":"Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle\u2010aged men","volume":"176","author":"Ollikainen","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0135","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","article-title":"P2Y12 H2 haplotype is associated with peripheral arterial disease: a case\u2013control study","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0140","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.STR.0000169922.79281.a5","article-title":"Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease","volume":"36","author":"Ziegler","year":"2005","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2350-8-59","article-title":"Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease","volume":"8","author":"Cavallari","year":"2007","journal-title":"BMC Med Genet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.thromres.2006.02.006","article-title":"Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel","volume":"119","author":"Lev","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","article-title":"Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease","volume":"116","author":"Angiolillo","year":"2005","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss\u2010of\u2010function polymorphism, but not CYP3A4 IVS10\u2003+\u200312G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high\u2010risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.mbc.0000164429.21040.0a","article-title":"P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate\u2010induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose","volume":"16","author":"Von Beckerath","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijcard.2007.12.118","article-title":"Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12\u2010ADP receptor gene","volume":"133","author":"Staritz","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0175","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/14622416.8.10.1413","article-title":"Pharmacogenomics of platelet responsiveness to aspirin","volume":"8","author":"Faraday","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0180","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/j.1538-7836.2005.01555.x","article-title":"Cyclooxygenase\u20101 haplotype modulates platelet response to aspirin","volume":"3","author":"Maree","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0185","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1055-9965.889.13.5","article-title":"Polymorphisms in PTGS1 (=COX\u20101) and risk of colorectal polyps","volume":"13","author":"Ulrich","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1160\/TH08-11-0753","article-title":"Cyclooxygenase\u20101 haplotype C50T\/A\u2010842G does not affect platelet response to aspirin","volume":"101","author":"Pettinella","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH05-07-0516","article-title":"Polymorphisms of COX\u20101 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients","volume":"95","author":"Lep\u00e4ntalo","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0200","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?","volume":"36","author":"Gonzalez\u2010Conejero","year":"2005","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0205","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0140-6736(98)05054-5","article-title":"Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation","volume":"353","author":"Undas","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0210","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(05)79320-X","article-title":"PlA2 polymorphism and efficacy of aspirin","volume":"351","author":"Cooke","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0215","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2004.11.045","article-title":"Aspirin resistance and a single gene","volume":"95","author":"Jefferson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0220","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0735-1097(03)00921-5","article-title":"Resistance in vitro to low\u2010dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia\/IIa) and C\u20105T Kozak (GP Ibalpha) polymorphisms","volume":"42","author":"Macchi","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0225","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/09537100600881412","article-title":"Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA\u2010100 system in patients with coronary artery disease","volume":"17","author":"Bernardo","year":"2006","journal-title":"Platelets"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0230","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1160\/TH06-10-0583","article-title":"Lack of association between the 807 C\/T polymorphism of glycoprotein Ia gene and post\u2010treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome","volume":"97","author":"Cuisset","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0235","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0240","series-title":"Enzymatic\u2010 and Transporter\u2010Based Drug\u2013Drug Interactions: Progress and Future Challenges","first-page":"51","article-title":"ADME pharmacogenetics and its impact on Drug\u2013Drug Interactions (Chapter 3)","author":"Kerb","year":"2009"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0255","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0260","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(92)90445-O","article-title":"Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel","volume":"44","author":"Savi","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0265","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","article-title":"CYP2C19 polymorphism and proton pump inhibitors","volume":"95","author":"Klotz","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clpt.2004.05.002","article-title":"CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole\u2010based quadruple therapy for eradication of Helicobacter pylori","volume":"76","author":"Schwab","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0275","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss\u2010of\u2010function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0280","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S\u2010mephenytoin metabolism in humans","volume":"269","author":"De Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0285","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0290","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"84","author":"Kim","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0295","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p\u2010450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0300","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on\u2010clopidogrel platelet reactivity associated with adverse 1\u2010year clinical outcome of elective percutaneous coronary intervention with drug\u2010eluting or bare\u2010metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0305","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","article-title":"Cytochrome P450 2C19 and non\u2010genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation","volume":"9","author":"Geisler","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0315","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0320","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00007691-200404000-00017","article-title":"Clinical aspects of the MDR1 (ABCB1) gene polymorphism","volume":"26","author":"Eichelbaum","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0330","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non\u2010ST acute coronary syndrome","volume":"7","author":"Fr\u00e9re","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0335","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0340","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","article-title":"Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects","volume":"5","author":"Fontana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0345","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/09537100500475844","article-title":"Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy","volume":"17","author":"Smith","year":"2006","journal-title":"Platelets"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2009.08.016","article-title":"Effect of comedication with proton pump inhibitors (PPIs) on post\u2010interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy","volume":"125","author":"Zuern","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0355","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0360","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double\u2010blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0365","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0370","unstructured":"Food and Drug Administration. Public\u2010health advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009."},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0375","unstructured":"Bhatt D. COGENT: A Prospective, Randomized, Placebo\u2010Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. Presented at: Transcatheter Cardiovascular Therapeutics; September 21\u201315, 2009; San Francisco."},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0380","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton\u2010pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0385","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.thromres.2007.01.012","article-title":"Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600\u2010mg loading dose of clopidogrel in 597 patients with non\u2010ST\u2010segment elevation acute coronary syndrome","volume":"120","author":"Cuisset","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0390","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point\u2010of\u2010care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU\u2010Assessing Ultegra) multicenter study","volume":"103","author":"Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0395","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mhj.2002.119763","article-title":"Reduced inhibition by abciximab in platelets with the PlA2 polymorphism","volume":"143","author":"Wheeler","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0400","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00008571-200210000-00011","article-title":"No evidence for an influence of the human platelet antigen\u20101 polymorphism on the antiplatelet effects of glycoprotein IIb\/IIIa inhibitors","volume":"12","author":"Weber","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0405","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long\u2010term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events","volume":"342","author":"O\u2019Neill","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0410","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","article-title":"Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0415","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V98.12.3256","article-title":"Genetic variation in glycoprotein IIb\/IIIa (GPIIb\/IIIa) as a determinant of the responses to an oral GPIIb\/IIIa antagonist in patients with unstable coronary syndromes","volume":"98","author":"O\u00b4Connor","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0420","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.ATV.20.7.1724","article-title":"The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E\u2010deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis","volume":"20","author":"Cayatte","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0425","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1159\/000216835","article-title":"The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population","volume":"27","author":"Bousser","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0430","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2222.2005.02220.x","article-title":"Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid\u2010intolerant asthma","volume":"35","author":"Kim","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0435","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ahj.2009.07.001","article-title":"The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. TRA*CER Executive and Steering Committees","volume":"158","year":"2009","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0440","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non\u2010urgent percutaneous coronary intervention: a randomised, double\u2010blind, placebo\u2010controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0445","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"Morrow","year":"2009","journal-title":"Am Heart J"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0450","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","article-title":"The in\u2010vitro effects of E5555, a protease\u2010activated receptor (PAR)\u20101 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease","volume":"102","author":"Serebruany","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0455","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2002-07-2149","article-title":"An intronic polymorphism in the PAR\u20101 gene is associated with platelet receptor density and the response to SFLLRN","volume":"101","author":"Dupont","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0460","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/01.ATV.20.2.585","article-title":"Protective effect of a thrombin receptor (protease\u2010activated receptor 1) gene polymorphism toward venous thromboembolism","volume":"20","author":"Arnaud","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0465","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment\u2010related severe toxicity: a prospective clinical trial by the German 5\u2010FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0470","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V92.8.2771","article-title":"Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease","volume":"92","author":"Gonzalez\u2010Conejero","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0475","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/01.STR.28.7.1392","article-title":"Polymorphisms of the human platelet antigens HPA\u20101, HPA\u20102, HPA\u20103, and HPA\u20105 on the platelet receptors for fibrinogen (GPIIb\/IIIa), von Willebrand factor (GPIb\/IX), and collagen (GPIa\/IIa) are not correlated with an increased risk for stroke","volume":"28","author":"Carlsson","year":"1997","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V94.1.46.413a27_46_51","article-title":"Prothrombotic genetic risk factors in young survivors of myocardial infarction","volume":"94","author":"Ardissino","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0485","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2006-03-013151","article-title":"Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy","volume":"109","author":"Bray","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0490","first-page":"140","article-title":"Study on T13254C polymorphism of the platelet membrane glycoprotein VI in Chinese Han population","volume":"26","author":"Yu","year":"2005","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0495","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/01.ATV.0000148708.44691.27","article-title":"Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP","volume":"251","author":"Hetherington","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0500","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0505","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1160\/TH06-05-0288","article-title":"Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers","volume":"96","author":"Fontana","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0510","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1291\/hypres.29.665","article-title":"Relationship between the thromboxane A2 receptor gene and susceptibility to cerebral infarction","volume":"29","author":"Kaneko","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0515","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome","volume":"101","author":"Frere","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0520","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss\u2010of\u2010function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2010.03791.x_bb0525","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss\u2010of\u2010function polymorphism to occurrence of drug\u2010eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2010.03791.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362211398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362211398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2010.03791.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:53:41Z","timestamp":1761533621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362211398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S153878362211398X"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03791.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet pharmacogenomics","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03791.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}